Renal function three years after early conversion from a calcineurin inhibitor to everolimus: Results from a randomized trial in kidney transplantation

Transplant International

Volumn 28, Issue 1, 2015, Pages 42-51

  Mjörnstedt, Lars ^a   Schwartz Sørensen, Søren ^b   Von Zur Mühlen, Bengt ^c   Jespersen, Bente ^d   Hansen, Jesper M ^e   Bistrup, Claus ^f   Andersson, Helene ^g   Gustafsson, Bengt ^a   Solbu, Dag ^h   Holdaas, Hallvard ⁱ  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b University of Copenhagen   (Denmark)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

^e GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^f ODENSE UNIVERSITY HOSPITAL   (Denmark)

^g LUND UNIVERSITY HOSPITAL   (Sweden)

^h Medical Department   (Norway)

ⁱ OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

calcineurin inhibitor; conversion; everolimus; glomerular filtration rate; kidney transplantation; long term; renal function

Indexed keywords

CHOLESTEROL; CORTICOSTEROID; CYCLOSPORIN; EVEROLIMUS; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MYCOPHENOLIC ACID; TRIACYLGLYCEROL; CALCINEURIN INHIBITOR; IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; BIOPSY PROVEN ACUTE REJECTION; CLINICAL ASSESSMENT; CONTROLLED STUDY; DEATH; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EDEMA; FEMALE; FIBROSING ALVEOLITIS; GASTROENTERITIS; GLOMERULUS FILTRATION RATE; GRAFT FAILURE; GRAFT SURVIVAL; HUMAN; HYPERLIPIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY FUNCTION; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PNEUMONIA; PROTEINURIA; PYELONEPHRITIS; RANDOMIZED CONTROLLED TRIAL; STEROID THERAPY; SURVIVAL RATE; THORAX PAIN; URINARY TRACT INFECTION; UROSEPSIS; AGED; ANALOGS AND DERIVATIVES; BIOPSY; CLINICAL TRIAL; FIBROSIS; GRAFT REJECTION; KIDNEY; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; RENAL INSUFFICIENCY; TREATMENT OUTCOME;

ADULT; AGED; BIOPSY; CALCINEURIN INHIBITORS; CYCLOSPORINE; FEMALE; FIBROSIS; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; RENAL INSUFFICIENCY; SIROLIMUS; TREATMENT OUTCOME;

EID: 84916594803     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/tri.12437     Document Type: Article

References (34)

1. Chapman JR,. Chronic calcineurin inhibitor nephrotoxicity-lest we forget. Am J Transplant 2011; 11: 693.
2. Flechner SM, Glyda M, Cockfield S, et al,. The ORION study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients. Am J Transplant 2011; 11: 1633.
3. Ekberg H, Tedesco-Silva H, Demirbas A, et al,. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562.
4. Srinivas TR, Schold JD, Guerra G, Eagan A, Bucci CM, Meier-Kriesche HU,. Mycophenolate mofetil/sirolimus compared to other common immunosuppressive regimens in kidney transplantation. Am J Transplant 2007; 7: 586.
5. Vincenti F, Ramos E, Brattstrom C, et al,. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation 2001; 71: 1282.
6. Asberg A, Midtvedt K, Line PD, et al,. Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients. Transplantation 2006; 82: 62.
7. Flechner SM, Kobashigawa J, Klintmalm G,. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity. Clin Transplant 2008; 22: 1.
8. Ekberg H,. Calcineurin inhibitor sparing in renal transplantation. Transplantation 2008; 86: 761.
9. Sprangers B, Kuypers DR, Vanrenterghem Y,. Immunosuppression: does one regimen fit all? Transplantation 2011; 92: 251.
10. Grinyó JM, Cruzado JM,. Mycophenolate mofetil and calcineurin-inhibitor reduction: recent progress. Am J Transplant 2009; 9: 2447.
11. Bemelman FJ, de Maar EF, Press RR, van Kan HJ, ten Berge IJ, Homan van der Heide JJ, de Fijter HW,. Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis. Transplantation 2009; 88: 421.
12. Rostaing L, Kamar N,. mTOR inhibitor/proliferation signal inhibitors: entering or leaving the field? J Nephrol 2010; 23: 133.
13. Guba M, Pratschke J, Hugo C, et al,. Renal function, efficacy, and safety of sirolimus and mycophenolate mofetil after short-term calcineurin inhibitor-based quadruple therapy in de novo renal transplant patients: one-year analysis of a randomized multicenter trial. Transplantation 2010; 90: 175.
14. Mjörnstedt L, Sørensen SS, von Zur Mühlen B, et al,. Improved renal function after early conversion from a calcineurin inhibitor to everolimus: a randomized trial in kidney transplantation. Am J Transplant 2012; 12: 2744.
15. Lebranchu Y, Thierry A, Toupance O, et al,. Efficacy and renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: CONCEPT study. Am J Transplant 2009; 9: 1115.
16. Weir MR, Mulgaonkar S, Chan L, et al,. Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: a randomized, controlled Spare-the-Nephron trial. Kidney Int 2011; 79: 897.
17. Budde K, Becker T, Arns W, et al,. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet 2011; 377: 837.
18. Schena FP, Pascoe MD, Alberu J, et al,. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009; 87: 233.
19. Holdaas H, Bentdal Ø, Pfeffer P, Mjørnstedt L, Solbu D, Midtvedt K,. Early, abrupt conversion of de novo renal transplant patients from cyclosporine to everolimus: results of a pilot study. Clin Transplant 2008; 22: 366.
20. Chhabra D, Alvarado A, Dalal P, et al,. Impact of calcineurin-inhibitor conversion to mTOR inhibitor on renal allograft function in a prednisone-free regimen. Am J Transplant 2013; 13: 2902.
21. Silva HT Jr, Felipe CR, Garcia VD, et al,. Planned randomized conversion from tacrolimus to sirolimus-based immunosuppressive regimen in de novo kidney transplant recipients. Am J Transplant 2013; 13: 3155.
22. Racusen LC, Solez K, Colvin RB, et al,. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713.
23. Lebranchu Y, Thierry A, Thervet E, et al,. Efficacy and safety of early cyclosporine conversion to sirolimus with continued MMF-four-year results of the Postconcept study. Am J Transplant 2011; 11: 1665.
24. Budde K, Lehner F, Sommerer C, et al,. Conversion from cyclosporine to everolimus at 4.5 months posttransplant: 3-year results from the randomized ZEUS study. Am J Transplant 2012; 12: 1528.
25. Russ G, Segoloni G, Oberbauer R, et al,. Superior outcomes in renal transplantation after early cyclosporine withdrawal and sirolimus maintenance therapy, regardless of baseline renal function. Transplantation 2005; 80: 1204.
26. Buron F, Hadj-Aissa A, Dubourg L, Morelon E, Steghens JP, Ducher M, Fauvel JP,. Estimating glomerular filtration rate in kidney transplant recipients: performance over time of four creatinine-based formulas. Transplantation 2011; 92: 1005.
27. White CA, Huang D, Akbari A, Garland J, Knoll GA,. Performance of creatinine-based estimates of GFR in kidney transplant recipients: a systematic review. Am J Kidney Dis 2008; 51: 1005.
28. Kovarik JM, Moore R, Wolf P, et al,. Screening for basiliximab exposure-response relationships in renal allotransplantation. Clin Transplant 1999; 13: 32.
29. Wang S, Wilkes MC, Leof EB, Hirschberg R., Noncanonical TGF-b pathways, mTORC1 and Ab1, in renal interstitial fibrogenesis. Am J Physiol Renal Physiol 2010; 298: F142.
30. Pontrelli P, Rossini M, Infante B, et al,. Rapamycin inhibits PAI-1 expression and reduces interstitial fibrosis and glomerulosclerosis in chronic allograft nephropathy. Transplantation 2008; 85: 125.
31. Servais A, Meas-Yedid V, Toupance O, et al,. Interstitial fibrosis quantification in renal transplant recipients randomized to continue cyclosporine or convert to sirolimus. Am J Transplant 2009; 9: 2552.
32. Yilmaz M, Nart A, Sen S, et al,. Progression of graft fibrosis under mammalian target of rapamycin inhibitor-based regimen. Nephrology (Carlton) 2010; 15: 653.
33. Kamar N, Del Bello A, Congy-Jolivet N, et al,. Incidence of donor-specific antibodies in kidney transplant patients following conversion to an everolimus-based calcineurin inhibitor-free regimen. Clin Transplant 2013; 27: 455.
34. Liefeldt L, Brakemeier S, Glander P, et al,. Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation. Am J Transplant 2012; 12: 1192.